: Friday, January 1, 2021, 7:39 PM IST
Govt will bear cost of vaccinating 30 crore individuals, not the entire population: COVID-19 task force head Dr Vinod Paul
The Central government has finally approved emergency use authorisation of the Oxford-AstraZeneca s coronavirus vaccine Covishield .
Only 30 crore people to be vaccinated, not the entire population: COVID-19 task force head Dr Vinod Paul
Photo Credit: PTI
India s COVID-19 task force head and NITI Aayog member, Dr Vinod Paul, on Friday said that the government with bear the cost of vaccinating 300 million (30 crore) individuals. These individuals will be from the priority groups as identified by the government and not the entire population. Notably, frontline workers, healthcare workers and the elderly will be among those targeted in the initial phase of vaccination.
COVID-19 Vaccine: No approval for Covaxin, expert panel seeks more data from Bharat Biotech
The meeting comes a day before dry run of the vaccine is slated to commence in all the states and Union Territories to equip the administration. A doctor displays the application of Covaxin in Tezpur, Assam. (Photo: PTI)
Share
Updated: Jan 1, 2021, 10:19 PM IST
The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine ‘Covaxin’ is not sufficient for grant of emergency use approval and has asked for more information, top sources informed news agency IANS.
SEC recommends Serum Institute of India vaccine Covishield for use in India
The Subject Experts Committee (SEC) has recommended Covishield to DCGI for use against COVID-19 virus in India. Serum Institute of India Vaccine has been approved by SEC.
Share
Updated: Jan 1, 2021, 07:49 PM IST
The Subject Experts Committee (SEC) has recommended Covishield to Drugs Controller General of India (DCGI) for use against COVID-19 virus in India. It was confirmed that 1.7 Lakh frontline workers will get the COVID-19 vaccine. Healthcare workers will be vaccinated in phase 1.
The 10-member Subject Expert Committee of India s Central Drug Standard Control Organisation on Friday (January 1) approved emergency use authorisation of the Oxford-AstraZeneca coronavirus vaccine Covishield . The expert panel had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute of India, the manufacturer of Covishield, and Bharat Biotech
Oxford COVID-19 vaccine gets approval for emergency use in India mid-day.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mid-day.com Daily Mail and Mail on Sunday newspapers.